Experts investigating suspected links between the AstraZeneca Covid-19 vaccine and blood clots have not found specific risk factors, including age, but are continuing their analyzes, the European Agency for Human Rights said on Wednesday. drugs (EMA).
"For the moment, the examinations have not identified any specific risk factors such as age, gender or a medical history including problems with blood clots for these very rare cases" reported from complications occurring in people vaccinated with AstraZeneca's product, said an EMA press release.
"No causal link with the vaccine is proven, but it is possible and additional analyzes are underway," the statement added.
READ ALSO>
Covid-19: criticized, AstraZeneca renames its vaccine Vaxzevria
The EMA said its safety committee is expected to issue "updated recommendations" on the controversial vaccine after its monthly meeting scheduled for next week.
"Its benefits (...) outweigh the possible risks"
Germany, like a number of other countries, on Tuesday advised against use of the product for younger people after reports of a few cases of blood clot problems, despite assurances from the EMA that the vaccine is safe. .
The EMA communicated after a meeting of experts on Monday to present their latest assessments of the AstraZeneca vaccine.
Their comments will be considered next week at the agency's security committee meeting.
Coronavirus Newsletter
Update on the Covid-19 epidemic
Subscribe to the newsletterAll newsletters
The European regulator reiterated its opinion already formulated on March 18: "Its benefits in the protection of people from Covid-19, with the associated risks of death and hospitalization, outweigh the possible risks".
